Hanyang Med Rev.  2016 Aug;36(3):168-173. 10.7599/hmr.2016.36.3.168.

Ocular Manifestations of Sarcoidosis: An Ophthalmologist's View

Affiliations
  • 1Department of Ophthalmology, Ewha Mokdong Hospital, School of Medicine, Ewha Womans University, Seoul, Korea. ytkim@ewha.ac.kr

Abstract

Sarcoidosis is a granulomatous disease which frequently involves eyes and adnexal tissues. Its prevalence of ocular involvement is reported as about 20%, although it varies widely according to authors, from 12% to 73%. Ocular sarcoidosis is present as various forms - uveitis, conjunctival involvement, optic nerve involvement, and orbital involvement. All the forms of uveitis - anterior uveitis, intermediate uveitis, posterior uveitis and panuveitis - can be shown in sarcoidosis. Because clinical manifestation, prognosis and treatment are determined by the location of uveitis, it is important to classify uveitis. Conjunctival involvement is not a sight-threatening condition in general, its diagnostic value may be of use. Optic nerve is the most commonly involved cranial nerve, which can impair vision. Subjects with visual impairment without any evidence of uveitis, optic nerve involvement should be suspected. Orbital involvement, especially lacrimal gland involvement is common, and it may cause mass-effect. Besides systemic administration of drugs, there are several localized treatments for ocular sarcoidosis - topical eye drops, intra/peri-ocular injection of agents.

Keyword

Sarcoidosis; Uveitis; Granuloma

MeSH Terms

Cranial Nerves
Granuloma
Lacrimal Apparatus
Ophthalmic Solutions
Optic Nerve
Orbit
Panuveitis
Prevalence
Prognosis
Sarcoidosis*
Uveitis
Uveitis, Anterior
Uveitis, Intermediate
Uveitis, Posterior
Vision Disorders
Ophthalmic Solutions

Cited by  1 articles

Ocular Manifestations of Systemic Diseases: The Eyes are the Windows of the Body
Heeyoon Cho
Hanyang Med Rev. 2016;36(3):143-145.    doi: 10.7599/hmr.2016.36.3.143.


Reference

1. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001; 164:1885–1889.
Article
2. Rothova A. Ocular involvement in sarcoidosis. Br J Ophthalmol. 2000; 84:110–116.
Article
3. Ohara K, Okubo A, Sasaki H, Kamata K. Intraocular manifestations of systemic sarcoidosis. Jpn J Ophthalmol. 1992; 36:452–457.
4. Lee SY, Lee HG, Kim DS, Kim JG, Chung H, Yoon YH. Ocular sarcoidosis in a Korean population. J Korean Med Sci. 2009; 24:413–419.
Article
5. Pathanapitoon K, Goossens JHM, van Tilborg TC, Kunavisarut P, Choovuthayakorn J, Rothova A. Ocular sarcoidosis in Thailand. Eye (Lond). 2010; 24:1669–1674.
Article
6. Goto H, Mochizuki M, Yamaki K, Kotake S, Usui M, Ohno S. Epidemiological survey of intraocular inflammation in Japan. Jpn J Ophthalmol. 2007; 51:41–44.
Article
7. Sharma OP. Sarcoidosis Around the World. Clin Chest Med. 2008; 29:357–363.
Article
8. Crick RP, Hoyle C, Smellie H. The eyes in sarcoidosis. Br J Ophthalmol. 1961; 45:461–481.
Article
9. Pasadhika S, Rosenbaum JT. Ocular Sarcoidosis. Clin Chest Med. 2015; 36:669–683.
Article
10. Myers TD, Smith JR, Lauer AK, Rosenbaum JT. Iris nodules associated with infectious uveitis. Br J Ophthalmol. 2002; 86:969–974.
Article
11. Fardeau C, Champion E, Massamba N, LeHoang P. Uveitic macular edema. Eye (Lond). 2016; Forthcoming.
Article
12. BenEzra D, Forrester JV, Nussenblatt RB, Tabbara K, Timonen P. Uveitis scoring system. Uveitis Scoring System. Berlin: Heidelberg: Springer;1991. p. 1–13.
13. Letocha CE, Shields JA, Goldberg RE. Retinal changes in sarcoidosis. Can J Ophthalmol. 1975; 10:184–192.
14. Goldberg NR, Jabs DA, Busingye J. Optical Coherence Tomography Imaging of Presumed Sarcoid Retinal and Optic Nerve Nodules. Ocul Immunol Inflamm. 2016; 24:293–296.
Article
15. Frohman LP, Grigorian R, Bielory L. Neuro-ophthalmic manifestations of sarcoidosis: clinical spectrum, evaluation, and management. J Neuroophthalmol. 2001; 21:132–137.
Article
16. Adema AY, ten Kate RW, Plaisier MB. Central retinal vein occlusion as an uncommon complication of sarcoidosis. Neth J Med. 2013; 71:134–136.
17. Paović J, Paović P, Vukosavljević M. Clinical and immunological features of retinal vasculitis in systemic diseases. Vojnosanit Pregl. 2009; 66:961–965.
Article
18. Momtchilova M, Pelosse B, Ngoma E, Laroche L. Branch retinal vein occlusion and sarcoidosis in a child: a case report. J Fr Ophtalmol. 2011; 34:243–247.
19. Nichols CW, Eagle RC, Yanoff M, Menocal NG. Conjunctival biopsy as an aid in the evaluation of the patient with suspected sarcoidosis. Ophthalmology. 1980; 87:287–291.
Article
20. Karcioglu ZA, Brear R. Conjunctival biopsy in sarcoidosis. Am J Ophthalmol. 1985; 99:68–73.
Article
21. Phillips YL, Eggenberger ER. Neuro-ophthalmic sarcoidosis. Curr Opin Ophthalmol. 2010; 21:423–429.
Article
22. Mansour AM. Ocular manifestations of various systemic diseases. Curr Opin Ophthalmol. 1996; 7:96–98.
Article
23. Nishida Y, Tian S, Isberg B, Tallstedt L, Lennerstrand G. MRI measurements of orbital tissues in dysthyroid ophthalmopathy. Graefes Arch Clin Exp Ophthalmol. 2001; 239:824–831.
Article
24. Demirci H, Christianson MD. Orbital and adnexal involvement in sarcoidosis: analysis of clinical features and systemic disease in 30 cases. Am J Ophthalmol. 2011; 151:1074–1080.e1.
Article
25. So WL, Hardy TG, McKelvie P. Atypical Clinical Presentation of Isolated Extraocular Muscle Sarcoid. Case Rep Ophthalmol Med. 2012; 2012:370258.
Article
26. Herbort CP, Rao NA, Mochizuki M. members of Scientific Committee of First International Workshop on Ocular Sarcoidosis. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm. 2009; 17:160–169.
Article
27. Nan K, Sun S, Li Y, Qu J, Li G, Luo L, Chen H, et al. Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection. Br J Ophthalmol. 2010; 94:654–658.
Article
28. Arcinue CA, Cerón OM, Foster CS. A Comparison Between the Fluocinolone Acetonide (Retisert) and Dexamethasone (Ozurdex) Intravitreal Implants in Uveitis. J Ocul Pharmacol Ther. 2013; 29:501–507.
Article
29. Pascual-Camps I, Hernández-Martínez P, Monje-Fernández L, Dolz-Marco R, Gallego-Pinazo R, Wu L, et al. Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders. J Ophthalmic Inflamm Infect. 2014; 4:26.
Article
Full Text Links
  • HMR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr